Features

Half of EU Clinical Trial Results Not Reported

September 17, 2018

Despite EU requirements for clinical trials to report results to the EU Clinical Trials Register within a year of a trial’s completion, sponsors have only reported about half of them so far.

Master Protocols Can Kickstart Clinical Trials

September 4, 2018

Master protocol designs have taken on new significance as sponsors, sites and regulators have come to recognize that decision points must be reached sooner—and the FDA is planning to issue new guidance on them in the coming weeks.

WCG, Inspire Team Up to Boost Trial Access

September 4, 2018

WCG has partnered with Inspire, a leading online health social network, in an effort to make it easier for patients—especially those with rare and genetic-based diseases—to find clinical trials that may help them.

Experts Ask FDA to Rethink Trial Exclusion Criteria

August 27, 2018

Ethical concerns about testing on vulnerable groups may be unnecessary and may be depriving trials of key critical data, a panel of experts says, urging the FDA to reconsider rigid rules excluding certain groups from clinical trials—or at least make decisions on a case-by-case basis.

FDA: New Flexibility for Blinding Cancer Trials

August 27, 2018

Cancer patients in clinical trials should be told whether they’ve been given placebos or experimental drugs if their tumors reappear or get worse—and patients and researchers should be told if sponsors are worried experimental drugs may be triggering bad reactions, the FDA says in new draft guidance.

Using placebos in double-blind, randomized trials is a traditional way to protect against bias, but it also raises “both practical and ethical concerns,” the agency says. For one thing, giving a mere placebo to someone who is getting sicker could be perceived as tantamount to denying them care. For another, many experimental drugs may have toxic side effects and it can be dangerous to keep patients and/or researchers in the dark about whether a med or disease is to blame for symptoms.

“For example, in a blinded immunotherapy trial, a patient who develops adverse events … may receive unnecessary treatments,” the FDA says. “Maintaining the blind [status] after disease progression could also affect a patient’s subsequent therapy, potentially preventing a patient who had been on a placebo from receiving an approved therapy, or delaying or preventing the patient’s entry into other clinical trials.”

In an effort to assuage concerns, many recent cancer trials take an open-label approach where patients are given an already-approved treatment instead of placebos to compare against the experimental one. Other trials use an add-on approach—all patients are given standard treatment plus either a placebo or an experimental treatment.

But in some cases there aren’t other treatments available. In those rare instances, the FDA suggests trials “un-blind” patients if their disease recurs or worsens while taking placebos.

The draft guidance—released late last week—says both patients and investigators should also be “un-blinded” if an experimental treatment causes harmful side effects and the patient may need another med or even surgery. But it recommends patients be allowed to stay in trials even if they’re un-blinded.

The FDA notes that if sponsors insist on keeping trials “blind” throughout, at the least, they need to carefully explain this may happen—and the risks involved—in informed consent documents before patients sign up.

Read the draft guidance here.

FDA: New Guidance for Expansion Cohort Trials

August 20, 2018

Expansion cohorts can help bring life-saving drugs to market quickly, but sponsors should be sure to update informed consent for patients and convene expert safety panels that meet regularly, the FDA says in new draft guidance.

NIH Delays Basic Brain Research Rules

August 20, 2018

NIH has delayed a controversial new policy that would have required basic brain and behavioral researchers to treat their work as clinical trials.